Aquinox Pharmaceuticals (NASDAQ:AQXP) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Monday, February 5th.
Several other research firms have also recently commented on AQXP. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 11th. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 target price on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $22.80.
Aquinox Pharmaceuticals (NASDAQ AQXP) opened at $16.00 on Monday. Aquinox Pharmaceuticals has a 1 year low of $10.02 and a 1 year high of $19.97.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AQXP. Alyeska Investment Group L.P. grew its stake in Aquinox Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock valued at $4,010,000 after acquiring an additional 5,046 shares during the period. Vanguard Group Inc. grew its stake in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the period. University of Notre Dame DU Lac grew its stake in Aquinox Pharmaceuticals by 32.0% in the fourth quarter. University of Notre Dame DU Lac now owns 251,091 shares of the company’s stock valued at $2,953,000 after acquiring an additional 60,808 shares during the period. Emory University grew its stake in Aquinox Pharmaceuticals by 38.3% in the fourth quarter. Emory University now owns 170,404 shares of the company’s stock valued at $2,004,000 after acquiring an additional 47,154 shares during the period. Finally, Northern Trust Corp grew its stake in Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after acquiring an additional 2,691 shares during the period. 96.21% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/bidaskclub-upgrades-aquinox-pharmaceuticals-aqxp-to-sell.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.